A Clinical Study of the ACRYSOF® IQ Extended Depth of Focus Intraocular Lens (IOL)
Public ClinicalTrials.gov record NCT03274986. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Randomized, Controlled, Multi-Center Clinical Study of the ACRYSOF® IQ Extended Depth of Focus IOL
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to demonstrate the safety and performance of ACRYSOF IQ extended depth of focus (EDF) intraocular lens (IOL) at Month 6. Depth of focus (DOF) is the amount of focal plane displacement behind a lens that does not degrade the image quality of a distant object. A larger DOF allows sharp images of closer objects and may provide improved vision at intermediate and near distances.
Study identification
- NCT ID
- NCT03274986
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 242 participants
Conditions and interventions
Conditions
Interventions
- ACRYSOF® IQ Extended Depth of Focus IOL Device
- ACRYSOF® IQ Monofocal IOL Device
- Cataract surgery Procedure
Device · Procedure
Eligibility (public fields only)
- Age range
- 22 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 10, 2017
- Primary completion
- Oct 15, 2018
- Completion
- Oct 15, 2018
- Last update posted
- Apr 6, 2020
2017 – 2018
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alcon Investigative Site | Birmingham | Alabama | 35213 | — |
| Alcon Investigative Site | Fort Collins | Colorado | 80528 | — |
| Alcon Investigative Site | Bradenton | Florida | 34209 | — |
| Alcon Investigative Site | Sebring | Florida | 33870 | — |
| Alcon Investigative Site | Gainesville | Georgia | 30501 | — |
| Alcon Investigative Site | Rock Island | Illinois | 61201 | — |
| Alcon Investigative Site | Cincinnati | Ohio | 45242 | — |
| Alcon Investigative Site | Allenwood | Pennsylvania | 17810 | — |
| Alcon Investigative Site | Kingston | Pennsylvania | 18704 | — |
| Alcon Investigative Site | West Mifflin | Pennsylvania | 15122 | — |
| Alcon Investigative Site | Sioux Falls | South Dakota | 57108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03274986, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 6, 2020 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03274986 live on ClinicalTrials.gov.